论文部分内容阅读
目的探讨人肾透明细胞癌(clear cell renal cell carcinoma,ccRCC)是否存在与细胞生长调节相关的转录因子19(TCF19)选择性剪接异构体,探索其表达特点及其与ccRCC发生的关系。方法通过选择性剪接数据库(alternative Spli-cing Database,ASD)对TCF19基因可能存在的选择性剪接异构体种类进行预测。设计可能存在的5种异构体引物,采用RT-PCR技术,在32例原发肾透明细胞癌的混合样本及癌旁组织的混合样本中分别检测预测异构体的表达,并对电泳所获条带进行克隆、测序。应用RT-PCR定量检测在各个组织样本中异构体TCF19-1、TCF19-3在原发肾癌及癌旁组织的表达差异。结果 ccRCC组织中存在2种新型TCF19替换剪接异构体(TCF19-1、TCF19-3)。RT-PCR检测结果发现这2种异构体在癌和癌旁组织中均表达,但TCF19-1在原发癌组织中表达率高于癌旁组织(P<0.001);TCF19-3在癌旁组织中的表达率与原发癌组织比较,差异无统计学意义(P=0.082)。结论首次发现ccRCC组织中存在2种TCF19选择性剪接异构体TCF19-1和TCF19-3,其中TCF19-1的表达可能与ccRCC有关。
Objective To investigate the existence of alternative splicing isoform 19 of transcription factor 19 (TCF19) in human clear cell renal cell carcinoma (ccRCC) and to explore its expression and its relationship with the occurrence of ccRCC. Methods The possible alternative splicing isoforms of TCF19 gene were predicted by alternative splicing database (ASD). The possible isomers of 5 isomers were designed and the predicted isoforms were detected by RT-PCR in mixed samples of 32 cases of primary clear cell renal cell carcinoma and adjacent tissues respectively. Obtained by the cloning, sequencing. RT-PCR was used to quantitatively detect the expression differences of TCF19-1 and TCF19-3 isoforms in primary renal cell carcinoma and paracancerous tissues in various tissue samples. Results Two novel TCF19 alternative splice isoforms (TCF19-1, TCF19-3) were present in the ccRCC tissues. RT-PCR results showed that these two isoforms were expressed in both cancer and paracancerous tissues, but TCF19-1 expression was higher in primary cancerous tissues than in paracancerous tissues (P <0.001) There was no significant difference in the expression rate between adjacent tissues and primary cancerous tissues (P = 0.082). Conclusions For the first time, there are two TCF19 alternative splice isoforms, TCF19-1 and TCF19-3, present in the ccRCC tissues, of which TCF19-1 expression may be related to the ccRCC.